Table 1.

Summary of patient-derived GBM

GBM Cells	In Vivo Phenotype		Genetic Alteration	CD44	PTEN	p-Akt (Ser473)	p-Akt (Thr308)	MGMT		Main Subtype	TMZ IC50 (µM)
	Invasiveness	Pathological Feature						Methylation	Protein
MGG4	N	Endothel. proliferation	MYC#	-	+	+	+	M	−	Not clear	32
MGG6	I	Conventional	EGFR#, MDM4#, PI3KC2B#, CDKN2A&B- -	NT	+	+	+	M	−	Classical	36
MGG8	I	PNET-like component	MYCN#, MDM2#, PDGFRA#, CDKN2A&B- -	+/-	+	−	+	M	−	PN	6
MGG18	N	Giant cell	NT	++	−	++	++	M	−	MES	315
MGG23	I	Gemistocytic	CDKN2A&B- -	++	−	++	+	U	+	MES	355
MGG24	I	Conventional	EGFR#	++	+	+	+	U/M	+	Classical	166
MGG29	N	Oligo-like component	NT	−/+	+	++	+	U	−	Not clear	>3000

Abbreviations: N, nodular; I, invasive; #, copy number amplifications; - -, homozygous deletion; PNET, primitive neuroectodermal tumor; PTEN, phosphatase and tensin homolog; +, positive; ++, strongly positive; −, negative; +/-, heterogeneous; M, methylated MGMT promoter; U, unmethylated MGMT promoter; U/M, a major unmethylated band with a weak methylated band; PN, proneural; MES, mesenchymal; NT, not tested.